< Back to Partners & supporters
The European Standards of Care for Newborn Health (ESCNH) are financially supported by the following industry partners. Industry partners have no influence on the content of the standards.
If you wish to learn more about an industry partner, please click on the link in the logo.
AstraZeneca is a global, science-led biopharmaceutical company that focuses
on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. Since 2019, Chiesi is the world’s largest biopharmaceutical group to be certified B Corp, meaning that its sustainability efforts are measured and assessed by the most ambitious global standards. The company aims at becoming net-zero by 2035. With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 30 countries, and counts more than 6,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.
The Nestlé Nutrition Institute (NNI) shares leading science-based information and education with health professionals, scientists and nutrition communities and stakeholders in an interactive way. As well as being a large publisher of nutritional papers and journals, the NNI organises and hosts internationally acclaimed workshops and symposia, making their findings available worldwide. It provides accredited continuing education programs for a wide range of healthcare professionals including doctors, nurses, midwifes and dietitians. By sharing neutral science-based information and education for healthcare professionals, the Institute fosters Science for Better Nutrition to contribute to the enhancement of the quality of people’s lives all over the world.
Prolacta Bioscience® Inc. is a privately-held life sciences company dedicated to Advancing the Science of Human Milk®. Prolacta is the world’s leading hospital provider of 100% human milk-based nutritional products that are changing the standard of care for extremely premature infants. In addition, the company is exploring the therapeutic potential of human milk across a wide spectrum of human diseases, including applications for infants requiring surgery for congenital cardiac and gastrointestinal disorders. Operating the world’s first pharmaceutical-grade human milk processing facilities, Prolacta leads the industry with the highest quality and safety standards for the screening and testing of donor milk. Prolacta is a global company with headquarters in Duarte, California.
Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Thanks to AbbVie for supporting the project from 2013 until 2020.
Thanks to Baxter for supporting the project from 2017 to 2019 and from 2021 until 2022.
Thanks to Dräger for supporting the project from 2013 until 2015.
Thanks to GE HealthCare for supporting the project from 2021 until 2023.
Thanks to Philips Avent for supporting the project from 2014 until 2019.
Thanks to Philips for supporting the project from 2018 until 2019.
Thanks to Shire for supporting the project from 2014 until 2018.
Thanks to Takeda for supporting the project from 2019 until 2020.
We thank all our industry partners for supporting the ESCNH.